medcitynews.com
Open in
urlscan Pro
2606:4700:20::ac43:45a1
Public Scan
Submitted URL: http://go.pardot.com/e/710433/tential-edge-over-sarepta-med-/f5m6g/512790016?h=Fe5kCOS2UnAXhCo7kNb7KOS6YJWEXhZxrrZ0TH...
Effective URL: https://medcitynews.com/2022/05/pepgen-ipo-nabs-108m-for-muscular-dystrophy-drug-with-potential-edge-over-sarepta-med/
Submission: On May 09 via api from US — Scanned from DE
Effective URL: https://medcitynews.com/2022/05/pepgen-ipo-nabs-108m-for-muscular-dystrophy-drug-with-potential-edge-over-sarepta-med/
Submission: On May 09 via api from US — Scanned from DE
Form analysis 6 forms found in the DOM
GET https://medcitynews.com/
<form method="get" class="search" action="https://medcitynews.com/" role="search">
<input type="text" class="field" name="s" value="" id="s" placeholder="Search …">
<button type="submit"><i class="fa fa-search"></i></button>
</form>GET https://medcitynews.com/
<form method="get" class="search" action="https://medcitynews.com/" role="search">
<input type="text" class="field" name="s" value="" id="s" placeholder="Search …">
<button type="submit"><i class="fa fa-search"></i></button>
</form>POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983
<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983" enctype="multipart/form-data"
id="hsForm_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" method="POST"
class="hs-form stacked hs-form-private hsForm_a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983_8d264594-7973-4a65-9ab5-5ae8fab14e5a"
data-form-id="a93d8b4e-029d-4de9-9599-c09510e52983" data-portal-id="2097126" target="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" data-reactid=".hbspt-forms-0">
<div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-0.1:$0"><label id="label-email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" class=""
placeholder="Enter your " for="email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" data-reactid=".hbspt-forms-0.1:$0.0"><span data-reactid=".hbspt-forms-0.1:$0.0.0"></span></label>
<legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-0.1:$0.1"></legend>
<div class="input" data-reactid=".hbspt-forms-0.1:$0.$email"><input id="email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" class="hs-input" type="email" name="email" required=""
placeholder="Your email address*" value="" autocomplete="email" data-reactid=".hbspt-forms-0.1:$0.$email.0" inputmode="email"></div>
</div><noscript data-reactid=".hbspt-forms-0.2"></noscript>
<div class="hs_submit hs-submit" data-reactid=".hbspt-forms-0.5">
<div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-0.5.0"></div>
<div class="actions" data-reactid=".hbspt-forms-0.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-0.5.1.0"></div>
</div><noscript data-reactid=".hbspt-forms-0.6"></noscript><input name="hs_context" type="hidden"
value="{"rumScriptExecuteTime":2220.9000000953674,"rumServiceResponseTime":2602.5,"rumFormRenderTime":2.8999998569488525,"rumTotalRenderTime":4826.5,"rumTotalRequestTime":345.5,"embedAtTimestamp":"1652111621369","formDefinitionUpdatedAt":"1464813666301","pageUrl":"https://medcitynews.com/2022/05/pepgen-ipo-nabs-108m-for-muscular-dystrophy-drug-with-potential-edge-over-sarepta-med/","pageTitle":"PepGen IPO nabs $108M for muscular dystrophy drug with potential edge over Sarepta med - MedCity News","source":"FormsNext-static-5.486","sourceName":"FormsNext","sourceVersion":"5.486","sourceVersionMajor":"5","sourceVersionMinor":"486","timestamp":1652111621375,"userAgent":"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/101.0.4951.41 Safari/537.36","originalEmbedContext":{"portalId":"2097126","formId":"a93d8b4e-029d-4de9-9599-c09510e52983","target":"#newsletter-form-mobile-interstitial","formInstanceId":"a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial"},"redirectUrl":"http://medcitynews.com/youre-subscribed/","formInstanceId":"a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial","renderedFieldsIds":["email"],"formTarget":"#newsletter-form-mobile-interstitial","correlationId":"38f0812e-1f25-47bb-ae67-f87aac91667c","hutk":"c858d3655c2c4567475597a4761aaeff","captchaStatus":"NOT_APPLICABLE"}"
data-reactid=".hbspt-forms-0.7"><iframe name="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" style="display:none;" data-reactid=".hbspt-forms-0.8"></iframe>
</form>POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983
<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983" enctype="multipart/form-data" id="hsForm_a93d8b4e-029d-4de9-9599-c09510e52983"
method="POST" class="hs-form stacked hs-form-private hsForm_a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983_4317e621-760a-47f2-a474-6ad66a18a296"
data-form-id="a93d8b4e-029d-4de9-9599-c09510e52983" data-portal-id="2097126" target="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983" data-reactid=".hbspt-forms-3">
<div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-3.1:$0"><label id="label-email-a93d8b4e-029d-4de9-9599-c09510e52983" class="" placeholder="Enter your " for="email-a93d8b4e-029d-4de9-9599-c09510e52983"
data-reactid=".hbspt-forms-3.1:$0.0"><span data-reactid=".hbspt-forms-3.1:$0.0.0"></span></label>
<legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-3.1:$0.1"></legend>
<div class="input" data-reactid=".hbspt-forms-3.1:$0.$email"><input id="email-a93d8b4e-029d-4de9-9599-c09510e52983" class="hs-input" type="email" name="email" required="" placeholder="Your email address*" value="" autocomplete="email"
data-reactid=".hbspt-forms-3.1:$0.$email.0" inputmode="email"></div>
</div><noscript data-reactid=".hbspt-forms-3.2"></noscript>
<div class="hs_submit hs-submit" data-reactid=".hbspt-forms-3.5">
<div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-3.5.0"></div>
<div class="actions" data-reactid=".hbspt-forms-3.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-3.5.1.0"></div>
</div><noscript data-reactid=".hbspt-forms-3.6"></noscript><input name="hs_context" type="hidden"
value="{"rumScriptExecuteTime":2220.9000000953674,"rumServiceResponseTime":5172.200000047684,"rumFormRenderTime":2.200000047683716,"rumTotalRenderTime":5192.200000047684,"rumTotalRequestTime":294.09999990463257,"embedAtTimestamp":"1652111623941","formDefinitionUpdatedAt":"1464813666301","pageUrl":"https://medcitynews.com/2022/05/pepgen-ipo-nabs-108m-for-muscular-dystrophy-drug-with-potential-edge-over-sarepta-med/","pageTitle":"PepGen IPO nabs $108M for muscular dystrophy drug with potential edge over Sarepta med - MedCity News","source":"FormsNext-static-5.486","sourceName":"FormsNext","sourceVersion":"5.486","sourceVersionMajor":"5","sourceVersionMinor":"486","timestamp":1652111623944,"userAgent":"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/101.0.4951.41 Safari/537.36","originalEmbedContext":{"portalId":"2097126","formId":"a93d8b4e-029d-4de9-9599-c09510e52983","target":"#signup-main-hubspot","redirectUrl":"http://medcitynews.com/youre-subscribed/"},"redirectUrl":"http://medcitynews.com/youre-subscribed/","renderedFieldsIds":["email"],"formTarget":"#signup-main-hubspot","correlationId":"ef05ef75-9ff3-413f-af87-e3f8ec6212f9","hutk":"c858d3655c2c4567475597a4761aaeff","captchaStatus":"NOT_APPLICABLE"}"
data-reactid=".hbspt-forms-3.7"><iframe name="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983" style="display:none;" data-reactid=".hbspt-forms-3.8"></iframe>
</form>POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983
<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983" enctype="multipart/form-data"
id="hsForm_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" method="POST"
class="hs-form stacked hs-form-private hsForm_a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983_2140112d-a74b-42ce-be1b-c42c0e2fa502"
data-form-id="a93d8b4e-029d-4de9-9599-c09510e52983" data-portal-id="2097126" target="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" data-reactid=".hbspt-forms-1">
<div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-1.1:$0"><label id="label-email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" class="" placeholder="Enter your "
for="email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" data-reactid=".hbspt-forms-1.1:$0.0"><span data-reactid=".hbspt-forms-1.1:$0.0.0"></span></label>
<legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-1.1:$0.1"></legend>
<div class="input" data-reactid=".hbspt-forms-1.1:$0.$email"><input id="email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" class="hs-input" type="email" name="email" required=""
placeholder="Your email address*" value="" autocomplete="email" data-reactid=".hbspt-forms-1.1:$0.$email.0" inputmode="email"></div>
</div><noscript data-reactid=".hbspt-forms-1.2"></noscript>
<div class="hs_submit hs-submit" data-reactid=".hbspt-forms-1.5">
<div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-1.5.0"></div>
<div class="actions" data-reactid=".hbspt-forms-1.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-1.5.1.0"></div>
</div><noscript data-reactid=".hbspt-forms-1.6"></noscript><input name="hs_context" type="hidden"
value="{"rumScriptExecuteTime":2220.9000000953674,"rumServiceResponseTime":3157.5,"rumFormRenderTime":2,"rumTotalRenderTime":4847.299999952316,"rumTotalRequestTime":823,"embedAtTimestamp":"1652111621938","formDefinitionUpdatedAt":"1464813666301","pageUrl":"https://medcitynews.com/2022/05/pepgen-ipo-nabs-108m-for-muscular-dystrophy-drug-with-potential-edge-over-sarepta-med/","pageTitle":"PepGen IPO nabs $108M for muscular dystrophy drug with potential edge over Sarepta med - MedCity News","source":"FormsNext-static-5.486","sourceName":"FormsNext","sourceVersion":"5.486","sourceVersionMajor":"5","sourceVersionMinor":"486","timestamp":1652111621944,"userAgent":"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/101.0.4951.41 Safari/537.36","originalEmbedContext":{"portalId":"2097126","formId":"a93d8b4e-029d-4de9-9599-c09510e52983","target":"#newsletter-form-sidebar","formInstanceId":"a93d8b4e-029d-4de9-9599-c09510e52983-sidebar"},"redirectUrl":"http://medcitynews.com/youre-subscribed/","formInstanceId":"a93d8b4e-029d-4de9-9599-c09510e52983-sidebar","renderedFieldsIds":["email"],"formTarget":"#newsletter-form-sidebar","correlationId":"216dba2b-b7f8-4778-a686-7c342d620087","hutk":"c858d3655c2c4567475597a4761aaeff","captchaStatus":"NOT_APPLICABLE"}"
data-reactid=".hbspt-forms-1.7"><iframe name="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" style="display:none;" data-reactid=".hbspt-forms-1.8"></iframe>
</form>POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/30083c7c-72db-412b-8a6e-e72e5b9308ce
<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/30083c7c-72db-412b-8a6e-e72e5b9308ce" enctype="multipart/form-data" id="hsForm_30083c7c-72db-412b-8a6e-e72e5b9308ce"
method="POST" class="hs-form stacked hs-form-private hsForm_30083c7c-72db-412b-8a6e-e72e5b9308ce hs-form-30083c7c-72db-412b-8a6e-e72e5b9308ce hs-form-30083c7c-72db-412b-8a6e-e72e5b9308ce_9970ae17-ce70-4184-951e-45a90f793ab4"
data-form-id="30083c7c-72db-412b-8a6e-e72e5b9308ce" data-portal-id="2097126" target="target_iframe_30083c7c-72db-412b-8a6e-e72e5b9308ce" data-reactid=".hbspt-forms-2">
<div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-2.1:$0"><label id="label-email-30083c7c-72db-412b-8a6e-e72e5b9308ce" class="" placeholder="Enter your " for="email-30083c7c-72db-412b-8a6e-e72e5b9308ce"
data-reactid=".hbspt-forms-2.1:$0.0"><span data-reactid=".hbspt-forms-2.1:$0.0.0"></span></label>
<legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-2.1:$0.1"></legend>
<div class="input" data-reactid=".hbspt-forms-2.1:$0.$email"><input id="email-30083c7c-72db-412b-8a6e-e72e5b9308ce" class="hs-input" type="email" name="email" required="" placeholder="Your email address*" value="" autocomplete="email"
data-reactid=".hbspt-forms-2.1:$0.$email.0" inputmode="email"></div>
</div><noscript data-reactid=".hbspt-forms-2.2"></noscript>
<div class="hs_submit hs-submit" data-reactid=".hbspt-forms-2.5">
<div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-2.5.0"></div>
<div class="actions" data-reactid=".hbspt-forms-2.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-2.5.1.0"></div>
</div><noscript data-reactid=".hbspt-forms-2.6"></noscript><input name="hs_context" type="hidden"
value="{"rumScriptExecuteTime":2220.9000000953674,"rumServiceResponseTime":5172.200000047684,"rumFormRenderTime":2,"rumTotalRenderTime":5174.299999952316,"rumTotalRequestTime":294.7999999523163,"embedAtTimestamp":"1652111623940","formDefinitionUpdatedAt":"1464813456785","pageUrl":"https://medcitynews.com/2022/05/pepgen-ipo-nabs-108m-for-muscular-dystrophy-drug-with-potential-edge-over-sarepta-med/","pageTitle":"PepGen IPO nabs $108M for muscular dystrophy drug with potential edge over Sarepta med - MedCity News","source":"FormsNext-static-5.486","sourceName":"FormsNext","sourceVersion":"5.486","sourceVersionMajor":"5","sourceVersionMinor":"486","timestamp":1652111623946,"userAgent":"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/101.0.4951.41 Safari/537.36","originalEmbedContext":{"portalId":"2097126","formId":"30083c7c-72db-412b-8a6e-e72e5b9308ce","target":"#interstitial_hubspot","redirectUrl":"http://medcitynews.com/youre-subscribed/"},"redirectUrl":"http://medcitynews.com/youre-subscribed/","renderedFieldsIds":["email"],"formTarget":"#interstitial_hubspot","correlationId":"602502c5-ba8f-4910-8424-e96ff798ea37","hutk":"c858d3655c2c4567475597a4761aaeff","captchaStatus":"NOT_APPLICABLE"}"
data-reactid=".hbspt-forms-2.7"><iframe name="target_iframe_30083c7c-72db-412b-8a6e-e72e5b9308ce" style="display:none;" data-reactid=".hbspt-forms-2.8"></iframe>
</form>Text Content
Menu Search * Home * News * Health Tech * Biopharma * Devices & Diagnostics * Consumer / Employer * Contributors * MedCity Influencers * MedCitizens * Events * Jobs * Research * Newsletters * About Us * Advertising * Contact us * Send Tips * Advertising * About * Twitter * Facebook * RSS * Subscribe via email X Close Signup Modal MEDCITY >> INBOX Get the latest industry news first when you subscribe to our daily newsletter. We will never sell or share your information without your consent. See our privacy policy. * Send Tips * Advertising * About * Twitter * Facebook * RSS * Subscribe via email MEDCITY NEWS RECLAIM YOUR PRIVACY BY BRINGING STI TESTING INTO THE HOME HOW CELL & GENE THERAPY STARTUPS CAN WARM UP TO INVESTORS IN THIS “BIOTECH NUCLEAR WINTER” THE NEW PARADIGM IN DRUG DEVELOPMENT: WHY PLATFORM TECHNOLOGY IS THE SOLUTION PATIENTS AND PAYERS NEED HOW IS AI MOVING THE NEEDLE IN THE PHARMACEUTICAL INDUSTRY? OVERHAULING PRIOR AUTHORIZATION: HOW TO ACHIEVE BETTER OUTCOMES AT A LOWER COST INVEST PITCH PERFECT WINNER: VINCERE HEALTH OFFERS UNDERSERVED PATIENTS A HOLISTIC SOLUTION TO QUIT SMOKING PEPGEN IPO NABS $108M FOR MUSCULAR DYSTROPHY DRUG WITH POTENTIAL EDGE OVER SAREPTA MED CREDIT BUREAUS ARE REMOVING MEDICAL DEBT, BUT HOSPITALS CAN PREVENT IT ARE YOU A STARTUP SEEKING TO TRANSFORM CLINICAL TRIALS? HERE’S WHY YOU SHOULD APPLY TO PITCH AT INVEST PHARMATECH. STARTUPDATES: NEW DEVELOPMENTS FOR HEALTHCARE STARTUPS HEALTHCARE HIRES OF NOTE EVEN WHEN IVF IS COVERED BY INSURANCE, HIGH BILLS AND HASSLES ABOUND NOVEL DRUG-DISCOVERY APPROACH LANDS BIG BACKERS THE NEXT BREAKTHROUGH IN CANCER TREATMENT HOW TO REGAIN TRUST IN UNDERSERVED COMMUNITIES SUCH THAT IT BOOSTS PANDEMIC READINESS * News * Health Tech * BioPharma * Devices & Diagnostics * Consumer / Employer * Contributors * MedCity Influencers * MedCitizens * Events * INVEST * INVEST PharmaTech * INVEST Digital Health * INVEST Population Health * Jobs * Research * Newsletters Be Sure to Share Your Insights on Our Brief MedCity Audience Survey for a Chance to Win a $250 AMEX Gift Card Pharma, BioPharma PEPGEN IPO NABS $108M FOR MUSCULAR DYSTROPHY DRUG WITH POTENTIAL EDGE OVER SAREPTA MED PEPGEN’S TECHNOLOGY IMPROVES THE DELIVERY OF A THERAPY TO MORE TISSUE TYPES AND THE CLINICAL-STAGE BIOTECH PLANS TO USE ITS IPO CASH TO CONTINUE DEVELOPING ITS LEAD PROGRAM FOR DUCHENNE MUSCULAR DYSTROPHY. MEANWHILE, EYE PRODUCTS GIANT BAUSCH + LOMB RETURNED TO THE PUBLIC MARKETS AS A STANDALONE COMPANY. BOTH THE PEPGEN AND BAUSCH + LOMB IPOS PRICED BELOW THEIR RESPECTIVE PRICE RANGES. By Frank Vinluan Post a comment / May 6, 2022 at 1:46 PM 1Shares The rare disorder Duchenne muscular dystrophy is treated with genetic medicines that get skeletal muscle cells to produce a version of the key protein that they lack. Though these therapies slow progression of this disease that robs patients of the ability to walk, patients typically die from Duchenne’s effects on the heart and breathing. Biotech company PepGen is developing a drug that delivers its therapeutic payload not only to skeletal muscle, but also to the diaphragm, cardiac muscle, and the central nervous system. PepGen’s scientists believe this broader delivery capability gives it an edge and the clinical-stage company has joined the public markets as it sets out to prove its approach. Promoted BETTER PRIMARY CARE ISN’T ONLY GOOD FOR HEALTH—IT’S GOOD FOR BUSINESS The rising cost of employer-sponsored healthcare makes it difficult for American businesses to compete globally. That doesn’t have to be the reality. Learn how one company changed its trajectory. Tom Gentile, CEO of Spirit AeroSystems & Richard Gephardt, Co-founder of SolidaritUS Health Cambridge, Massachusetts-based PepGen initially planned to offer 7.2 million shares in the range of $13 to $15 each, which would have raised $108 at the $14 per share midpoint. The company was able to raise that amount, but it had to offer more shares do so. Late Thursday, PepGen priced its offering of 9 million shares at $12 apiece. Those shares began trading on the Nasdaq Friday under the stock symbol “PEPG.” For diseases with a known genetic cause, one therapeutic approach is an antisense oligonucleotide, a type of therapy made from small pieces of synthetic DNA or RNA. The four FDA-approved therapies for Duchenne—three from Sarepta Therapeutics and one from NS Pharma—are all antisense oligonucleotides. PepGen said in its IPO filing that the limiting factor for oligonucleotide-based drugs is delivery. “On their own, oligonucleotides therapeutics are not readily distributed to heart and skeletal muscle, the key tissues affected in neuromuscular diseases, and are not efficiently taken up into these cells,” the company said. “To address this challenge, we engineered our proprietary EDO technology to optimize tissue penetration, cellular uptake and nuclear delivery, which we believe may enhance the therapeutic activity of oligonucleotides and improve the tolerability of these genetic medicines.” EDO stands for Enhanced Delivery Oligonucleotide. This technology platform engineers peptides so that they can better carry oligonucleotide cargos to desired tissue destinations. In preclinical research, PepGen has shown its technology can transport oligonucleotides into tissue types that include smooth, skeletal, and cardiac muscle, as well as the central nervous system. Promoted HOW MEDTECH CAN BETTER INTEGRATE WITH HEALTHCARE WORKFLOWS THROUGH DIGITAL SOLUTIONS Healthcare industry is transitioning to value-based care models. That’s why the medical device industry's ability to continue the development of life-changing innovations will rely on demonstrating how new technology fits under this value-based paradigm. To build future-ready solutions, it’s important to focus on choosing the right tools and technology partners. The Innovaccer Health Cloud is well-positioned to do just that! Innovaccer's Rishav Krishna & Smriti Khera PepGen’s lead program, called PGN-EDO51, is intended to treat Duchenne patients whose disease can be addressed by getting the cell’s protein-making machinery to skip exon 51, one of the segments of a gene containing the code that is translated into a protein. This approach leads to a shortened version of the key muscle protein that Duchenne patients lack. Exon skipping is the same approach taken by Sarepta’s first FDA-approved Duchenne therapy, Exondys 51. Sarepta is developing a next-generation exon 51-skipping drug that uses cell-penetrating peptides to improve delivery. That therapeutic candidate, SRP-5051, is currently in Phase 2 testing. PepGen said in its IPO filing that it conducted a monkey study compared its experimental drug against a molecule that’s equivalent to Sarepta’s next-generation exon-skipper. According to PepGen, results showed a greater than 70% increase in exon 51 skipping in skeletal muscle, including the diaphragm. The PepGen therapy also showed greater activity. Last month, PepGen began a Phase 1 single-ascending dose study enrolling healthy volunteers in Canada. Preliminary data from the clinical trial are expected by the end of this year. The EDO platform has yielded a second program, PGN-EDODM1, which the biotech is developing as a treatment for myotonic dystrophy type 1 (DM1), a rare muscle disorder that currently has no FDA-approved treatments. PepGen said in its prospectus that it expects to submit an investigational new drug application for a DM1 therapy in the first half of next year. A second Duchenne therapy, PGN-ENDO53, is being developed to address patients who can be treated by skipping exon 53. PepGen said it expects to begin a test of that drug in monkeys in the second half of 2022. Besides further Duchenne research, PepGen said it plans to study potential applications of its technology in additional indications that include neuromuscular diseases and neurological disorders. The science behind PepGen’s drugs is based on more than a decade of research from the labs of Matthew Wood, a professor of neuroscience at the University of Oxford, and Mike Gait, emeritus scientist at the Medical Research Council of United Kingdom Research and Innovation. PepGen was founded in 2018; in 2020, the biotech closed a $45 million Series A round of funding. Prior to the IPO, PepGen had raised $163.9 million, the company said in its prospectus. Its most recent financing was a $112.5 million crossover round that closed last August. RA Capital is PepGen’s largest shareholder with a 23.7% stake after the IPO, according to the prospectus. Oxford Sciences Enterprises, a firm that takes a stake in Oxford University science spinouts, owns 18.3% of the company. As of the end of 2021, PepGen had $132.8 million in cash, the prospectus shows. Combined with the IPO proceeds, PepGen plans to spend about $70 million on completing Phase 1 testing of PGN-EDO51 and continuing on to a planned Phase 2a study. Another $45 million is set aside for completing a Phase 1/2 clinical trial for PGN-EDODM1, while about $30 million is earmarked for further development of its drug pipeline and platform. Following the IPO, PepGen estimates its cash holdings will carry the company into the first half of 2025. Bausch + Lomb raises $630M in return to the public markets Bausch + Lomb is trading on the New York Stock Exchange again after completing an IPO that comes 15 after the iconic eye products company was taken private. On Thursday evening, the company priced its offering of 35 million shares at $18 apiece, well below the $21 to $24 price range the company had previously set. In addition to its debut on the NYSE, Vaughan, Ontario-based Bausch + Lomb also listed shares on the Toronto Stock Exchange. The stock trades on both exchanges under the stock symbol “BLCO.” The Bausch + Lomb IPO marks the company’s separation from Bausch Health Companies (formerly Valeant Pharmaceuticals), the company that acquired it in 2013. Bausch + Lomb was initially taken private in 2007 with its acquisition by private equity firms for $4.7 billion. Bausch + Lomb won’t receive any of the IPO proceeds, which will go to Bausch Health. In advance of the IPO filing in January, Bausch Health CEO Joe Papa said that his firm will use the cash from the IPO to pay down debt. Public domain image by the Centers for Disease Control and Prevention 1Shares TOPICS biotech IPO, Cambridge, Clinical Trials, duchenne muscular dystrophy, Massachusetts, oligonucleotide, PepGen, rare diseases HEAR THE LATEST INDUSTRY NEWS FIRST. SIGN UP FOR OUR DAILY NEWSLETTER. We will never sell or share your information without your consent. See our privacy policy. Promoted THE RISE OF VIRTUAL-FIRST CARE: BRIDGING THE GAP BETWEEN ONLINE AND OFFLINE PATIENT EXPERIENCES In a webinar sponsored by Wheel, health tech executives will explore how telehealth is increasingly becoming the first point of interaction between patients and providers and the potential for hybrid care models to improve the patient experience, health outcomes, and deliver cost savings. Wheel and MedCity News MEDCITY INVEST PHARMATECH JOIN US AT INVEST PHARMATECH 2022 MedCity INVEST PharmaTech, a virtual event to be held July 26, 2022 is a virtual executive summit where established biopharma companies gather with health tech and digital health innovators to transform the industry. Reserve your spot now.>> GOT NEWS? SEND US A TIP MEDCITY >> INBOX Get the latest industry news first when you subscribe to our newsletter. We will never sell or share your information without your consent. See our privacy policy. Promoted IMPORTANCE OF PATIENT CAPITAL IN LIFE SCIENCES TSX Venture Exchange has a strong history of helping early stage health and life sciences companies raise patient capital for research and development purposes. Daniel Lubienietzky, Toronto Stock Exchange × HEAR THE LATEST INDUSTRY NEWS FIRST. SIGN UP FOR OUR DAILY NEWSLETTER. No thanks We will never sell or share your information without your consent. See our privacy policy. Advertise About Newsletter Our Sites * * * * * * * © 2022 Breaking Media, Inc. All rights reserved. Registration or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. Privacy Center | Do not sell my information 1Shares WELCOME TO MEDCITYNEWS MEDCITYNEWS ASKS FOR YOUR CONSENT TO USE YOUR PERSONAL DATA TO: * perm_identity Personalised ads and content, ad and content measurement, audience insights and product development * devices Store and/or access information on a device expand_moreremove Learn more * How can I change my choice? * What if I don't consent? * How does legitimate interest work? * Do I have to consent to everything? Your personal data will be processed and information from your device (cookies, unique identifiers, and other device data) may be stored by, accessed by and shared with third party vendors, or used specifically by this site or app. Some vendors may process your personal data on the basis of legitimate interest, which you can object to by managing your options below. Look for a link at the bottom of this page or in our privacy policy where you can withdraw consent. Consent Manage options arrow_back Data preferences MANAGE YOUR DATA You can choose how your personal data is used. Vendors want your permission to do the following: TCF vendors help_outline STORE AND/OR ACCESS INFORMATION ON A DEVICE Cookies, device identifiers, or other information can be stored or accessed on your device for the purposes presented to you. View details Consent SELECT BASIC ADS Ads can be shown to you based on the content you’re viewing, the app you’re using, your approximate location, or your device type. View details ConsentLegitimate interesthelp_outline CREATE A PERSONALISED ADS PROFILE A profile can be built about you and your interests to show you personalised ads that are relevant to you. View details ConsentLegitimate interesthelp_outline SELECT PERSONALISED ADS Personalised ads can be shown to you based on a profile about you. View details ConsentLegitimate interesthelp_outline CREATE A PERSONALISED CONTENT PROFILE A profile can be built about you and your interests to show you personalised content that is relevant to you. View details ConsentLegitimate interesthelp_outline SELECT PERSONALISED CONTENT Personalised content can be shown to you based on a profile about you. View details ConsentLegitimate interesthelp_outline MEASURE AD PERFORMANCE The performance and effectiveness of ads that you see or interact with can be measured. View details ConsentLegitimate interesthelp_outline MEASURE CONTENT PERFORMANCE The performance and effectiveness of content that you see or interact with can be measured. View details ConsentLegitimate interesthelp_outline APPLY MARKET RESEARCH TO GENERATE AUDIENCE INSIGHTS Market research can be used to learn more about the audiences who visit sites/apps and view ads. View details ConsentLegitimate interesthelp_outline DEVELOP AND IMPROVE PRODUCTS Your data can be used to improve existing systems and software, and to develop new products View details ConsentLegitimate interesthelp_outline ENSURE SECURITY, PREVENT FRAUD, AND DEBUG help_outline Your data can be used to monitor for and prevent fraudulent activity, and ensure systems and processes work properly and securely. View details TECHNICALLY DELIVER ADS OR CONTENT help_outline Your device can receive and send information that allows you to see and interact with ads and content. View details MATCH AND COMBINE OFFLINE DATA SOURCES help_outline Data from offline data sources can be combined with your online activity in support of one or more purposes View details LINK DIFFERENT DEVICES help_outline Different devices can be determined as belonging to you or your household in support of one or more of purposes. View details RECEIVE AND USE AUTOMATICALLY-SENT DEVICE CHARACTERISTICS FOR IDENTIFICATION help_outline Your device might be distinguished from other devices based on information it automatically sends, such as IP address or browser type. View details USE PRECISE GEOLOCATION DATA Your precise geolocation data can be used in support of one or more purposes. This means your location can be accurate to within several meters. View details Consent Vendor preferences Accept all Confirm choices arrow_back Vendor preferences CONFIRM OUR VENDORS Vendors can use your data to provide services. Declining a vendor can stop them from using the data you shared. TCF vendors help_outline EXPONENTIAL INTERACTIVE, INC D/B/A VDX.TV Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ROQ.AD INC. Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch Consent INDEX EXCHANGE, INC. Cookie duration: 395 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline QUANTCAST INTERNATIONAL LIMITED Cookie duration: 397 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BEESWAXIO CORPORATION Cookie duration: 395 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SOVRN HOLDINGS INC Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADIKTEEV Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline RTB HOUSE S.A. Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline WIDESPACE AB Cookie duration: 372 (days). Cookie duration resets each session. View details | Storage details | Privacy policylaunch Consent THE TRADE DESK Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADMETRICS GMBH Doesn't use cookies. View details | Privacy policylaunch Consent AMOBEE INC. Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline EPSILON Cookie duration: 400 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline YAHOO EMEA LIMITED Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADVENTORI SAS Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TRIPLELIFT, INC. Cookie duration: 90 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline XANDR, INC. Cookie duration: 90 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NEORY GMBH Cookie duration: 90 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline UNRULY GROUP LLC Cookie duration: 395 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NEURAL.ONE Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADITION TECHNOLOGIES GMBH Cookie duration: 90 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ACTIVE AGENT (ADITION TECHNOLOGIES GMBH) Cookie duration: 90 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TABOOLA EUROPE LIMITED Cookie duration: 366 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SMART ADSERVER Cookie duration: 396 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADFORM Cookie duration: 60 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MAGNITE, INC. Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADARA MEDIA UNLIMITED Cookie duration: 730 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SIFT MEDIA, INC Doesn't use cookies. View details | Privacy policylaunch Consent RAKUTEN MARKETING LLC Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline AVOCET SYSTEMS LIMITED Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline LIFESTREET CORPORATION Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SIZMEK BY AMAZON Cookie duration: 396 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline OPENX Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline YIELDLAB AG Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ROKU ADVERTISING SERVICES Cookie duration: 731 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NANO INTERACTIVE GMBH Cookie duration: 182 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SIMPLIFI HOLDINGS INC Cookie duration: 366 (days). View details | Privacy policylaunch Consent PUBMATIC, INC. Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline COMSCORE B.V. Cookie duration: 720 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline FLASHTALKING, INC. Cookie duration: 730 (days). View details | Privacy policylaunch Consent MEDIAMATH, INC. Cookie duration: 393 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SMAATO, INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SEMASIO GMBH Cookie duration: 366 (days). Cookie duration resets each session. View details | Storage details | Privacy policylaunch Consent CRIMTAN HOLDINGS LIMITED Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SCENE STEALER LIMITED Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BETGENIUS LTD Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TRESENSA TECHNOLOGIES, INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline CRITEO SA Cookie duration: 390 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADLOOX SA Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BLIS MEDIA LIMITED Cookie duration: 400 (days). Cookie duration resets each session. Uses other forms of storage. View details | Storage details | Privacy policylaunch ConsentLegitimate interesthelp_outline LOTAME SOLUTIONS, INC Cookie duration: 274 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline LIVERAMP, INC. Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline GROUPM UK LIMITED Cookie duration: 395 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline LOOPME LIMITED Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline DYNATA LLC Cookie duration: 365 (days). View details | Privacy policylaunch Consent FUSIO BY S4M Cookie duration: 1 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TEEMO SA Cookie duration: 30 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline DOUBLEVERIFY INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BIDSWITCH GMBH Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline IPONWEB GMBH Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NEXTROLL, INC. Cookie duration: 395 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TEADS Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline STRÖER SSP GMBH (SSP) Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline STRÖER SSP GMBH (DSP) Cookie duration: 90 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline PLATFORM161 B.V. Cookie duration: 396 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADACADO TECHNOLOGIES INC. (DBA ADACADO) Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MEETRICS GMBH Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SMADEX, S.L.U. Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BOMBORA INC. Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SPOTX, INC Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline EASYMEDIA GMBH Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch Consent REMERGE GMBH Doesn't use cookies. View details | Privacy policylaunch Consent ADVANCED STORE GMBH Cookie duration: 24856 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MAGNITE CTV, INC. Cookie duration: 366 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline DELTA PROJECTS AB Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline USEMAX ADVERTISEMENT (EMEGO GMBH) Cookie duration: 365 (days). Cookie duration resets each session. View details | Storage details | Privacy policylaunch ConsentLegitimate interesthelp_outline EMETRIQ GMBH Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline PUBLICIS MEDIA GMBH Cookie duration: 90 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch Consent MCCANN DISCIPLINE LTD Cookie duration: 14 (days). View details | Privacy policylaunch Consent ONETAG LIMITED Cookie duration: 741 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline CLOUD TECHNOLOGIES S.A. Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SMARTOLOGY LIMITED Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline IMPROVE DIGITAL Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADOBE ADVERTISING CLOUD Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BANNERFLOW AB Cookie duration: 366 (days). View details | Storage details | Privacy policylaunch ConsentLegitimate interesthelp_outline TABMO SAS Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline INTEGRAL AD SCIENCE, INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline WIZALY Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch Consent WEBORAMA Cookie duration: 393 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline JIVOX CORPORATION Cookie duration: 90 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MOBILE PROFESSIONALS BV / SAGE+ARCHER BV Doesn't use cookies. View details | Privacy policylaunch Consent ON DEVICE RESEARCH LIMITED Cookie duration: 30 (days). View details | Privacy policylaunch Consent EXACTAG GMBH Cookie duration: 180 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline CELTRA, INC. Doesn't use cookies. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MAINADV SRL Cookie duration: 1 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline GEMIUS SA Cookie duration: 395 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch Consent THE KANTAR GROUP LIMITED Cookie duration: 914 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline IMPACT TECH INC. Cookie duration: 720 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NIELSEN MARKETING CLOUD Cookie duration: 120 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SOLOCAL Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline PIXALATE, INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ORACLE DATA CLOUD Cookie duration: 180 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NUMBERLY Cookie duration: 396 (days). View details | Privacy policylaunch Consent AUDIENCEPROJECT APS Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline EFFILIATION / EFFINITY Cookie duration: 60 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ARRIVALIST CO Cookie duration: 730 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SEENTHIS AB Doesn't use cookies. View details | Privacy policylaunch COMMANDERS ACT Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch Consent TRAVEL AUDIENCE GMBH Cookie duration: 397 (days). Cookie duration resets each session. View details | Storage details | Privacy policylaunch Consent HUMAN Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADLUDIO LTD. Doesn't use cookies. View details | Privacy policylaunch Consent NEODATA GROUP SRL Cookie duration: 366 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline INNOVID INC. Cookie duration: 92 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TACTIC™ REAL-TIME MARKETING AS Cookie duration: Uses session cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NEUSTAR, INC., A TRANSUNION COMPANY Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SUBLIMESKINZ - ADLEDGE Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SALESFORCE.COM, INC. Cookie duration: 180 (days). Uses other forms of storage. View details | Privacy policylaunch Consent VERVE GROUP EUROPE GMBH Doesn't use cookies. View details | Privacy policylaunch Consent KOCHAVA INC. Doesn't use cookies. View details | Privacy policylaunch Consent OTTO (GMBH & CO KG) Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADOBE AUDIENCE MANAGER, ADOBE EXPERIENCE PLATFORM Cookie duration: 180 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline LOCALSENSOR B.V. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ONLINE SOLUTION Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline RELAY42 NETHERLANDS B.V. Cookie duration: 731 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline GP ONE GMBH Cookie duration: Uses session cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline LIFTOFF MOBILE, INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MINDTAKE RESEARCH GMBH Cookie duration: 93 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline AAX LLC Cookie duration: 2191 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline CINT AB Cookie duration: 730 (days). View details | Privacy policylaunch Consent GOOGLE ADVERTISING PRODUCTS Cookie duration: 396 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline GFK SE Cookie duration: 730 (days). Uses other forms of storage. View details | Privacy policylaunch Consent REVJET Cookie duration: 730 (days). View details | Privacy policylaunch Consent DIGISEG APS Doesn't use cookies. View details | Privacy policylaunch Consent PROTECTED MEDIA LTD Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline CLINCH LABS LTD Cookie duration: 730 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline HEARTS & SCIENCE MÜNCHEN GMBH Cookie duration: 60 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline AMAZON ADVERTISING Cookie duration: 396 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MOLOCO, INC. Cookie duration: Uses session cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline OBJECTIVE PARTNERS BV Cookie duration: 90 (days). Cookie duration resets each session. View details | Privacy policylaunch Consent EBAY INC Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline General vendors help_outline GSKINNER Privacy policylaunch Consent AKAMAI Privacy policylaunch Consent FACEBOOK Privacy policylaunch Consent AUNICA Privacy policylaunch Consent BOOKING.COM Privacy policylaunch Consent C3 METRICS Privacy policylaunch Consent IBM Privacy policylaunch Consent ADTRIBA Privacy policylaunch Consent PULSEPOINT Privacy policylaunch Consent DEMANDBASE Privacy policylaunch Consent EVIDON Privacy policylaunch Consent CUBED Privacy policylaunch Consent HURRA.COM Privacy policylaunch Consent OPTOMATON Privacy policylaunch Consent INTELLIAD Privacy policylaunch Consent ANALIGHTS Privacy policylaunch Consent DSTILLERY Privacy policylaunch Consent DMA INSTITUTE Privacy policylaunch Consent ZMS Privacy policylaunch Consent DENTSU AEGIS NETWORK Privacy policylaunch Consent IGNITION ONE Privacy policylaunch Consent OMNICOM MEDIA GROUP Privacy policylaunch Consent RESONATE Privacy policylaunch Consent CENTRO Privacy policylaunch Consent SOJERN Privacy policylaunch Consent HAENSEL AMS Privacy policylaunch Consent BDSK HANDELS GMBH & CO. KG Privacy policylaunch Consent VIDEOLOGY Privacy policylaunch Consent TRADEDOUBLER AB Privacy policylaunch Consent TRUSTARC Privacy policylaunch Consent TRUEFFECT Privacy policylaunch Consent MARKETING SCIENCE CONSULTING GROUP, INC. Privacy policylaunch Consent DENTSU Privacy policylaunch Consent ESSENS Privacy policylaunch Consent TRAVEL DATA COLLECTIVE Privacy policylaunch Consent ADVOLUTION.CONTROL Privacy policylaunch Consent VIMEO Privacy policylaunch Consent ENSIGHTEN Privacy policylaunch Consent ADMAXIM Privacy policylaunch Consent BATCH MEDIA Privacy policylaunch Consent VODAFONE GMBH Privacy policylaunch Consent NETQUEST Privacy policylaunch Consent MANAGE.COM Privacy policylaunch Consent CLOUDFLARE Privacy policylaunch Consent SCOOTA Privacy policylaunch Consent HAVAS MEDIA FRANCE - DBI Privacy policylaunch Consent NETFLIX Privacy policylaunch Consent MACROMILL GROUP Privacy policylaunch Consent EBUILDERS Privacy policylaunch Consent APPLOVIN CORP. Privacy policylaunch Consent FRACTIONAL MEDIA Privacy policylaunch Consent RACKSPACE Privacy policylaunch Consent MSI-ACI Privacy policylaunch Consent NAVEGG Privacy policylaunch Consent ADMEDO Privacy policylaunch Consent MOBITRANS Privacy policylaunch Consent ADEX Privacy policylaunch Consent SPOTAD Privacy policylaunch Consent AARKI Privacy policylaunch Consent SFR Privacy policylaunch Consent CABLATO Privacy policylaunch Consent WAYSTACK Privacy policylaunch Consent Accept all Confirm choices Close Share this Article Friend's Email Address Your Name Your Email Address Comments Send Email Email sent! ×